The effect of metformin on esophageal cancer risk in patients with type 2 diabetes mellitus: a systematic review and meta ‑ analysis
Clin. transl. oncol. (Print)
; 23(2): 275-282, feb. 2021.
Article
em En
| IBECS
| ID: ibc-220611
Biblioteca responsável:
ES1.1
Localização: ES15.1 - BNCS
ABSTRACT
Objective Recently, numerous studies have yielded inconsistent results regarding the effect of metformin on esophageal cancer risk in type 2 diabetes mellitus patients. The purpose of this study is to systematically assess this effect using meta-analysis. Methods We searched clinical studies on metformin and esophageal cancer risk in PubMed, Embase, and the Cochrane Library. After literature screening, a series of meta-analyses were conducted using RevMan 5.3 software. The pooled hazard ratio (HR) and the corresponding 95% confidence interval (CI) were used as the effect size. Results Five eligible studies (four cohort studies and one casecontrol study) were included for our meta-analysis using a random-effect model. The analysis showed that metformin could not reduce esophageal cancer risk in type 2 diabetes mellitus patients (HR 0.88, 95% CI 0.601.28, P > 0.05). Subgroup analyses by geographic location showed that metformin significantly reduced esophageal cancer risk in Asian patients with type 2 diabetes mellitus (HR 0.59, 95% CI 0.390.91, P = 0.02), without heterogeneity between studies (P = 0.80 and I2 = 0%). Conclusions Overall, our systematic review and meta-analysis demonstrate that metformin does not reduce esophageal cancer risk in type 2 diabetes mellitus patients. However, a significant reduction in esophageal cancer risk in Asian populations remains to be clarified (AU)
Palavras-chave
Buscar no Google
Coleções:
06-national
/
ES
Base de dados:
IBECS
Assunto principal:
Neoplasias Esofágicas
/
Diabetes Mellitus Tipo 2
/
Hipoglicemiantes
/
Metformina
Limite:
Humans
Idioma:
En
Revista:
Clin. transl. oncol. (Print)
Ano de publicação:
2021
Tipo de documento:
Article